Publications by authors named "KeJun Nan"

Claim this Profile
C
Circ-malat1 promotes gastric cell growth via miR-154-5p/CCND2.
Lina Li, Liuqing Yang, Yuzhen Wang, Kejun Nan

Front Genet· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study.
Shun Lu, Lin Wu, Qiming Wang, Ziping Wang, Dongqing Lv, Kejun Nan

J Thorac Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update.
Feng Wang, Gong Chen, Zhen Zhang, Ying Yuan, Yi Wang, Kejun Nan

Cancer Commun (Lond)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retraction: miRNA-302b Suppresses Human Hepatocellular Carcinoma by Targeting AKT2.
Lumin Wang, Jiayi Yao, Xiaogang Zhang, Bo Guo, Xiaofeng Le, Kejun Nan

Mol Cancer Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retraction Note: Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway.
Xiao Fu, Mengjie Liu, Shengyang Qu, Jiequn Ma, Yamin Zhang, Kejun Nan

J Exp Clin Cancer Res· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global, regional and national burden of non-Hodgkin lymphoma from 1990 to 2017: estimates from global burden of disease study in 2017.
Haifeng Sun, Li Xue, Yahuan Guo, Jianqiang Du, Kejun Nan

Ann Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study.
Yizhuo Zhao, Qiming Wang, Li Zhang, Jianhua Shi, Zhehai Wang, Kejun Nan

Transl Lung Cancer Res· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line chemotherapy plus immune checkpoint inhibitors or bevacizumab in advanced non-squamous non-small-cell lung cancer without mutations or fusions.
Panpan Jiang, Luying Geng, Ziyang Mao, Qinyang Wang, Wenjuan Wang, Nanzheng Chen, Kejun Nan

Immunotherapy· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Colon cancer cells secreted CXCL11 via RBP-Jκ to facilitated tumour-associated macrophage-induced cancer metastasis.
Mengjie Liu, Xiao Fu, Lili Jiang, Jiequn Ma, Xiaoqiang Zheng, Kejun Nan

J Cell Mol Med· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial.
Jianhua Shi, Guimin Chen, Haitao Wang, Xiuxiu Wang, Baohui Han, Kejun Nan

Thorac Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors.
Xiao-Hui Jia, Lu-Ying Geng, Pan-Pan Jiang, Hong Xu, Ke-Jun Nan

J Exp Clin Cancer Res· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circ_0000218 plays a carcinogenic role in laryngeal cancer through regulating microRNA-139-3p/Smad3 axis.
Yiyang Bai, Jia Hou, Xiao Wang, Luying Geng, Xiaohui Jia, Kejun Nan

Pathol Res Pract· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in -Mutant Advanced Lung Adenocarcinoma.
Luochengling Xiang, Xiao Fu, Xiao Wang, Wenyuan Li, Xiaoqiang Zheng, Kejun Nan

Front Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a Five-Gene Signature for Predicting Survival in Malignant Pleural Mesothelioma Patients.
Yiyang Bai, Xiao Wang, Jia Hou, Luying Geng, Xuan Liang, Kejun Nan

Front Genet· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial.
Ying Cheng, Baohui Han, Kai Li, Qiming Wang, Li Zhang, Kejun Nan

Cancer Med· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MicroRNA-561 Affects Proliferation and Cell Cycle Transition Through PTEN/AKT Signaling Pathway by Targeting P-REX2a in NSCLC.
ZiJun Liao, Qi Zheng, Ting Wei, YanBing Zhang, JieQun Ma, KeJun Nan

Oncol Res· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial.
Zhonghan Zhang, Yunpeng Yang, Ping Lu, Xiaoqin Li, Jianhua Chang, Kejun Nan

Ann Transl Med· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NK cell-produced IFN-γ regulates cell growth and apoptosis of colorectal cancer by regulating IL-15.
Feng Cui, Di Qu, Ruya Sun, Mingming Zhang, Kejun Nan

Exp Ther Med· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reactive Oxygen Species Are Involved in the Development of Gastric Cancer and Gastric Cancer-Related Depression through ABL1-Mediated Inflammation Signaling Pathway.
Tianhe Huang, Fuling Zhou, Xiaohan Yuan, Tian Yang, Xuan Liang, Kejun Nan

Oxid Med Cell Longev· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CNV Detection from Circulating Tumor DNA in Late Stage Non-Small Cell Lung Cancer Patients.
Hao Peng, Lan Lu, Zisong Zhou, Jian Liu, Dadong Zhang, Kejun Nan

Genes (Basel)· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial.
Lili Wang, Zhen He, Sen Yang, Hong Tang, Yufeng Wu, Kejun Nan

Transl Lung Cancer Res· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating CD16+CD56+ nature killer cells indicate the prognosis of colorectal cancer after initial chemotherapy.
Feng Cui, Di Qu, Ruya Sun, Kejun Nan

Med Oncol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathological and prognostic significance of pretreatment thrombocytosis in patients with endometrial cancer: a meta-analysis.
Yi-Yang Bai, Lan Du, Li Jing, Tao Tian, Xuan Liang, Ke-Jun Nan

Cancer Manag Res· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303.
Xiaoyan Si, Li Zhang, Hanping Wang, Xiaotong Zhang, Mengzhao Wang, Kejun Nan

Thorac Cancer· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment.
Jing Wang, Yizhuo Zhao, Qiming Wang, Li Zhang, Jianhua Shi, Kejun Nan

Cancer Biol Med· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis